Loading...
XSHE300683
Market cap396mUSD
Jan 09, Last price  
22.23CNY
1D
-2.93%
1Q
-13.20%
IPO
-57.02%
Name

Wuhan Hiteck Biological Pharma Co Ltd

Chart & Performance

D1W1MN
XSHE:300683 chart
P/E
—
P/S
4.83
EPS
—
Div Yield, %
0.08%
Shrs. gr., 5y
4.66%
Rev. gr., 5y
0.38%
Revenues
602m
-12.54%
355,992,686548,791,132679,406,628770,974,124750,258,800590,873,499620,163,188524,123,427614,683,452688,625,991602,284,306
Net income
-121m
77,654,086109,911,99583,346,512157,053,448142,389,64994,137,74563,035,065027,654,2280-120,822,819
CFO
5m
-89.98%
76,821,220135,404,687159,887,188143,859,87183,076,51173,423,47963,027,543012,088,24753,033,6645,314,257
Dividend
Jul 01, 20200.16 CNY/sh
Earnings
May 16, 2025

Profile

Wuhan Hiteck Biological Pharma Co.,Ltd, a biopharmaceutical company, engages in the research and development, production, and sale of bio engineering products and freeze-dried powder injection in China. Its products include Jinlujie, a mouse nerve growth factor for injection; omeprazole sodium for injection; cyclic adenosine phosphate; Xinye, an acyclovir dispensable tablets; Bingbing Horse & Dragon, an indomethacin furazolidone suppository drug; Xunkeyuan, a tinidazole suppository drug; and Shufu, a nimodipine sustained release tablets. The company also provides measles virus and rubella virus nucleic acid detection kit; mycoplasma isolation and identification kit and culture tube; bacterial vaginosis rapid detection kit; measles virus IgG antibody detection kit; and coronavirus N-protein detection kit. In addition, it offers Lopinavir and Ritonavir APIs; and intermediates. The company offers its products in the field of nervous system and oncology. Wuhan Hiteck Biological Pharma Co.,Ltd was founded in 1992 and is based in Wuhan, China.
URL
http://www.hiteck.com.cn/
IPO date
Aug 08, 2017
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
602,284
-12.54%
688,626
12.03%
Cost of revenue
663,736
635,014
Unusual Expense (Income)
NOPBT
(61,452)
53,612
NOPBT Margin
7.79%
Operating Taxes
(23,743)
74
Tax Rate
0.14%
NOPAT
(37,709)
53,538
Net income
(120,823)
 
Dividends
(2,201)
(1,339)
Dividend yield
0.05%
0.03%
Proceeds from repurchase of equity
(417)
(200)
BB yield
0.01%
0.00%
Debt
Debt current
7,323
59,149
Long-term debt
47,125
46,091
Deferred revenue
30,468
27,897
Other long-term liabilities
45,916
2,451
Net debt
(1,061,250)
(787,282)
Cash flow
Cash from operating activities
5,314
53,034
CAPEX
(167,441)
Cash from investing activities
(491,930)
525,355
Cash from financing activities
248,291
(12,287)
FCF
141,871
286,953
Balance
Cash
1,088,923
892,521
Long term investments
26,775
Excess cash
1,085,583
858,089
Stockholders' equity
605,337
778,054
Invested Capital
2,010,611
1,681,795
ROIC
3.05%
ROCE
2.17%
EV
Common stock shares outstanding
129,917
122,104
Price
36.04
1.81%
35.40
-40.56%
Market cap
4,682,209
8.32%
4,322,487
-31.77%
EV
3,638,325
3,559,992
EBITDA
11,254
107,085
EV/EBITDA
323.29
33.24
Interest
2,390
1,117
Interest/NOPBT
2.08%